Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein.
Elevated plasma homocysteine (homocysteinemia) are presumed to be responsible for the development of coronary artery disease, however, the precise etiology is unclear. We examined the possibility that the adduct formed from the reaction between homocysteine thiolactone, a metabolic product of homocysteine, and apolipoprotein B-100 lysyl residues of low density lipoprotein (LDL) was immunogenic. New Zealand White rabbits were immunized with this adduct at 6-week intervals. Antisera collected following the 3rd immunization was assayed for antibody titers using solid phase ELISA techniques. Titers (defined as the inverse of the greatest serum dilution in which there was a significant difference (P < 0.05) between the percentage antibody bound from the antiserum and the pre-immune serum) were approximately 10(5). In competition-based ELISAs, homocysteine thiolactone-treated LDL competed for binding with the antiserum, as the 50% inhibitory concentration was approximately 10 microg/ml. Neither homocysteine, homocystine (homocysteine disulfide), nor Cu2-oxidized LDL competed for binding. LDL in which lysyl residues were derivatized by acetylation or methylation were not recognized by the antiserum. Homocysteine thiolactone-treated plasma competed for binding to the antiserum, whereas native plasma did not. All lipoprotein fractions from the homocysteine thiolactone-treated plasma competed for binding to the antiserum. We conclude that homocysteine thiolactone-modified LDL is highly immunogenic and specific for homocysteine thiolactone-modified lysines. The potential for using this antibody as a diagnostic tool for measuring plasma homocysteine concentrations and the implications for understanding diseases induced by homocysteinemia are discussed.
Ferguson
E
E
Biophysics Research Institute, Medical College of Wisconsin, Milwaukee 53226, USA.
Parthasarathy
S
S
Joseph
J
J
Kalyanaraman
B
B
D000918:Antibody Specificity; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000737:chemistry / Q000276:immunology*; D001667:Binding, Competitive; D003538:Cystamine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006710:Homocysteine / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000276:immunology*; D008239:Lysine / Q000031:analogs & derivatives / Q000276:immunology; D014652:Vascular Diseases / Q000209:etiology
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D006710:Homocysteine; C029174:homocystamine; C007957:homocysteine thiolactone; D008239:Lysine; D003538:Cystamine